Apimeds Pharmaceuticals US (APUS) Assets Average (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Assets Average came in at $86.7 million in Q4 2025, up 776.07% on a QoQ basis from $9.9 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Assets Average (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Assets Average data on file, last reported at $86.7 million in Q4 2025.
- Quarterly Assets Average changed N/A year-over-year to $86.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $86.7 million (changed N/A YoY) and the FY2025 annual result came in at $82.1 million, up 37634.85% from the prior year.
- Assets Average climbed to $86.7 million in Q4 2025, from $9.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $86.7 million in Q4 2025 to a low of $136480.5 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 5.97 Bn |
| 10 | Apimeds Pharmaceuticals US | 7.20 Mn | 7.20 Mn | - | 145.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 86.72 Mn |
| Sep 30, 2025 | 9.90 Mn |
| Jun 30, 2025 | 5.40 Mn |
| Mar 31, 2025 | 136,480.50 |